Alternatively spliced tissue factor A crippled protein in coagulation or a key player in non-haemostatic processes?

Author(s):
Berg, Y.W. van den; Versteeg, H.H. (0000-0003-4294-175X)
Published
2010
Publication type
Article / Letter to editor

Abstract

Full-length tissue factor (fITF) initiates coagulation, but also exerts non-hemostatic functions such as inflammation and angiogenesis I through,protease activated receptors (PARs) In 2003 a soluble variant of fITF was described which results from alternative splicing Since its discovery the role of alternatively spliced; tissue factor (asTF) in coagulation has been debated. asTF may have pro-coagulant propeites, but due to structural differences when compared to fITF, asTF coagulant function may be relatively low. Nevertheless, similar to I fITF, asTF appears to have non-hemostatic properties, asTF expression in tumors correlates with increased tumor size, vessel I number and poor survival in some cancer I types, and drives tumor growth in animal I models Interestingly, unlike fITF, asTF does not promote angiogenesis through activating PARs but:rather:via integrin ligation. fITF is a critical determinant'in cardiovascular disease but little is known about asTF in cardiovascular disease asTF is,Produced by monocytes. and macrophages thus macrophage-derived asTF may contribute:to atherosclerotic disease In conclusion, unraveling asTF's non-hemostatic, properties may generate new insights in the pathophysiology and diagnostics of cancer and cardiovascular disease.

Angiogenesis cancer cardiovascular disease integrins human endothelial-cells factor expression procoagulant activity cancer-cells tumor-growth angiogenesis events progression thrombosis mice
Date issued
2010-08-31
Language
English
Is part of
H�mostaseologie (2010), Vol. 30, no. 3, p. 144
hdl
1887/110053